Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2–4 (SPACE trial)

INTRODUCTION: Hereditary proximal spinal muscular atrophy (SMA) is caused by homozygous loss of function of the survival motor neuron 1 gene. The main characteristic of SMA is degeneration of alpha motor neurons in the anterior horn of the spinal cord, but recent studies in animal models and patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Stam, Marloes, Wadman, Renske I, Wijngaarde, Camiel A, Bartels, Bart, Asselman, Fay-Lynn, Otto, Louise A M, Goedee, H Stephan, Habets, Laura E, de Groot, Janke F, Schoenmakers, Marja A G C, Cuppen, Inge, van den Berg, Leonard H, van der Pol, W Ludo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067401/
https://www.ncbi.nlm.nih.gov/pubmed/30061431
http://dx.doi.org/10.1136/bmjopen-2017-019932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067401/
https://www.ncbi.nlm.nih.gov/pubmed/30061431
http://dx.doi.org/10.1136/bmjopen-2017-019932

Ejemplares similares